The US Court of Appeals for the Fifth Circuit upholds the FTC’s decision that two pharmaceutical companies entered an anticompetitive reverse payment settlement (Endo / Impax)

On April 13, the U.S. Court of Appeals for the Fifth Circuit affirmed the Federal Trade Commission’s decision that Impax Laboratories entered an anticompetitive “reverse payment” settlement with Endo Pharmaceuticals. This case was the FTC’s first fully litigated reverse payment case since the Supreme Court’s 2013 decision in FTC v. Actavis holding that reverse payment settlements can violate the antitrust laws. Background In 2016, the FTC alleged that Impax entered an illegal “reverse payment” settlement agreement with Endo in 2010 that delayed generic entry by more than two years in exchange for payments worth over $100 million. Specifically, the FTC alleged that Impax could have entered with a generic version of extended-release oxymorphone to compete with Endo’s Opana ER product in

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Cleary Gottlieb Steen & Hamilton (Washington)
  • Cleary Gottlieb Steen & Hamilton (Washington)
  • Cleary Gottlieb Steen & Hamilton (Washington)
  • Cleary Gottlieb Steen & Hamilton (Washington)

Citation

Kenneth Reinker, Bruce Hoffman, Kathleen W. Bradish, George S. Cary, The US Court of Appeals for the Fifth Circuit upholds the FTC’s decision that two pharmaceutical companies entered an anticompetitive reverse payment settlement (Endo / Impax), 13 avril 2021, e-Competitions April 2021, Art. N° 100691

Visites 171

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues